1. Scrip

Spotlight Back On Indian Rotavirus Vaccine Controversy

 
• By Anju Ghangurde

A public interest litigation has sought to revive efforts to access segregated trial data from a locally developed oral rotavirus vaccine in India, amid concerns that it might be associated with a higher risk of intussusception in certain pockets of the country. In a further dimension, an expert panel recently brought up a "representation" on the inclusion of intussusception in the vaccine's package insert.

A public interest litigation (PIL) filed in the Supreme Court of India is believed to be seeking segregated data of a trial site for a domestically developed oral rotavirus vaccine in Vellore in southern India, to determine if certain sections of the population are potentially more susceptible to the vaccine's potential adverse effects.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Focus On Asia

More from Scrip

Executives On The Move: Nine CEOs, Six CMOs And Three CFOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Novo Nordisk and Takeda, plus Nxera Pharma nabs chief commercial officer from AstraZeneca.

Will China’s Retaliatory Tariffs Galvanize Manufacturing Onshoring?

 
• By Dexter Jie Yan

China’s imposed large retaliatory tariffs on US pharmaceuticals on 10 April, but some domestic firms with in-licensed, US-origin assets were already moving to localized manufacturing.

Compounding Unlikely To Solve GLP-1 Affordable Access Issues

 
• By Alaric DeArment

The end of semaglutide and tirzepatide shortages means large-scale compounding is declining, ICER noted. But compounded versions – and the demand for them – are likely here to stay.